Brief: Hybrigenics gets authorization for clinical Phase II study of inecalcitol
14/12/2015 16:49
Dec 14 (Reuters) - Hybrigenics SA ALHYG.PA :
* Receives green light for a clinical Phase II double blind
study against placebo of inecalcitol in acute myeloid leukemia
* Authorization received from national agency for the
security of medicines in France
Source text: http://bit.ly/1m1A1XX
Further company coverage: ALHYG.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 698 3920;))
Recent news on Aton SA
See all newsBrief: Hybrigenics SA Says Hybrigenics Re-Brands To 'Aton', Commits EUR 15Million To Support Its New Growth And Development Strategy Over Next Three Years
Brief: Hybrigenics 2022 Net Loss EUR 0.5 Million
Brief: Hybrigenics Presents Progress Of B Cell Design Subsidiary
Brief: Hybrigenics Targets EUR 60 Mln Of Turnover By 2025
Brief: Hybrigenics H1 Operating Loss Widens To EUR 0.2 Million